High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation in multiple sclerosis: preliminary clinical results of approbation of the method
Authors:
- A. Yu. PolushinAPA. Yu. Polushin
- Yu. R. ZalyalovYZYu. R. Zalyalov
- A. N. GavrilenkoAGA. N. Gavrilenko
- A. A. TsynchenkoATA. A. Tsynchenko
- I. B. SkibaISI. B. Skiba
- M. A. EstrinaMEM. A. Estrina
- E. V. BabenkoEBE. V. Babenko
- A. A. GotovchikovAGA. A. Gotovchikov
- L. N. PrakhovaLPL. N. Prakhova
- А. Г. ИльвесАИА. Г. Ильвес
- N. A. TotolyanNTN. A. Totolyan
Open Access
- 23 November 2022
- journal article
- research article
- Published by Medical Informational Agency Publishers in Russian neurological Journal
- Vol. 27 (5) , 25-35
Abstract
Introduction. In 2018–2020, a study was conducted in the Russian Federation on the efficacy and safety of highdose immunosuppressive therapy with autologous hematopoietic stem cell transplantation (HDIT-AHSCT) in multiple sclerosis (MS).The aim of the study was to analyze preliminary data on the effectiveness and safety of the HDIT-AHSCT in patients with MS who participated in the clinical approbation of the method.Material and methods. 21 patients were included in a single-center Pavlov University (Saint Petersburg) observational study. In 10 patients (47.6%) the Expanded Disability Status Scale (EDSS) ranged from 1.0 to 4.0, in 10 — from 4.5 to 6.0 points, 1 patient with primary-progressive MS (PPMS) had 6.5 EDSS points. Cyclophosphamide conditioning regimen (200 mg/kg) in combination with rituximab (1000 mg/m2) was used. Neurological assessment (EDSS, SNRS, T25-FW, 9-HPT, PASAT, MoCA, HADS) and brain MRI were performed before and after 12 months. The early and long-term complications of HDIT-AHSCT were also analyzed.Results. One year after HDIT-AHSCT improvement and significant improvement were noted in 10 patients (47.6%), stabilization — in 8 (38.1%), relapse/progression — in 3 (14.3%). A lower effect was observed in patients with spasticity of more than 3 points by the MAS. According to MRI data 18 patients (85.7%) had stabilization of MS with no disease activity after 1 year, that met the No Evidence of Disease Activity (NEDA) criteria. Long-term complications included autoimmune thyroiditis (n = 1) and amenorrhea in two patients older than 38 years. No TRM were registered during the observation period.Conclusion. HDIT-AHSCT is an effective method of treating patients with multiple sclerosis. The results of the research demonstrate the safety and effectiveness of HDIT-AHSCT and it can be used to expanse the opportunities for providing treatment of patients with MS in the Russian Federation.Keywords
This publication has 27 references indexed in Scilit:
- Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple SclerosisJAMA Neurology, 2017
- NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugsMultiple Sclerosis Journal, 2016
- Association of Nonmyeloablative Hematopoietic Stem Cell Transplantation With Neurological Disability in Patients With Relapsing-Remitting Multiple SclerosisJAMA, 2015
- World Medical Association Declaration of HelsinkiJAMA, 2013
- National estimate of multiple sclerosis incidence in France (2001–2007)Multiple Sclerosis Journal, 2012
- Ovarian failure following cancer treatment: current management and quality of lifeHuman Reproduction, 2008
- Incidence of multiple sclerosis in the United KingdomJournal of Neurology, 2007
- Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the bone marrow transplant survivor studyBone Marrow Transplantation, 2006
- Regional and Temporal Variation in the Incidence of Multiple Sclerosis in Finland 1979–1993Neuroepidemiology, 2000
- Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot studyBone Marrow Transplantation, 1997